“I believe one person can produce enough 5-MeO-DMT to supply everyone that would ever want it.”
“Our researchers will isolate and study all of the potentially ‘magic’ molecules in mushrooms.”
The entourage effect caught PSR’s eye back in early 2019. What are experts saying about the theory now and how are psychedelic research companies approaching it?
This is the first time since the 1970s that a Canadian company has legally cultivated and harvested psychedelic mushrooms.
The research will use cutting-edge technology to attempt to remove undesirable side-effects from drugs targeting GPCRs, including the serotonin receptors where psychedelics act.
This collaboration will determine the full scope of the pharmacological effects of several synthetic tryptamine compounds.
This technology developed by MindMed and Liechti Lab may help ease some of the concerns surrounding psychedelic therapy.
UK Health Technology Assessment body raises questions over the clinical and cost-effectiveness of Spravato (esketamine).
The scope and validity of this patent will depend on how x-ray diffraction data is interpreted.
A look into the promising potential of artificial intelligence in tackling unmet medical needs in mental healthcare